Stoke Therapeutics, Inc.

États‑Unis d’Amérique

Commandez votre montre hebdomadaire Stoke Therapeutics, Inc.
Quantité totale PI 68
Rang # Quantité totale PI 20 295
Note d'activité PI 2,6/5.0    48
Rang # Activité PI 15 110
Symbole boursier STOK (nasdaq)
ISIN US86150R1077
Capitalisation 728M  (USD)
Industrie Biotechnology
Secteur Healthcare
Classe Nice dominante Services scientifiques, technolo...

Brevets

Marques

21 2
12 1
31 0
1
 
Dernier brevet 2025 - Methods for treating conditions ...
Premier brevet 2016 - Antisense oligomers for treatmen...
Dernière marque 2025 - STK-001
Première marque 2016 - STOKE THERAPEUTICS

Industrie (Classification de Nice)

Derniers inventions, produits et services

2025 P/S nucleotides for scientific and research use pharmaceutical preparations research and development ...
Invention Methods for treating conditions and diseases. VSCN1ASCN1A gene. The dosing regimens and methods c...
Invention Treatment of eye diseases and diagnostics. e.g.,OPA1e.g., e.g., low-contrast visual acuity test) ...
Invention Compounds for treatment of conditions and diseases. Compounds are provided herein that can promo...
2024 Invention Methods for treating conditions and diseases. Provided herein are methods for treating condition...
Invention Methods for treating conditions and diseases. SCN1ASCN1A gene and modulating the expression level...
Invention Opa1 antisense oligomers for treatment of conditions and diseases. Alternative splicing events in...
Invention Opa1 antisense oligomers for treatment of conditions and diseases. Agents that target a processe...
Invention Compounds and methods for treating human subjects. Described herein are compounds and methods tha...
Invention Antisense oligomer formulations. VVV1.1 protein in the subject.
2023 Invention Antisense oligomers for treatment of non-sense mediated rna decay based conditions and diseases. ...
Invention Antisense oligomers for treatment of conditions and diseases. Alternative splicing events in SCN...
Invention Opa1 antisense oligomers for treatment of conditions and diseases. Alternative splicing events i...
Invention Compositions for treatment of conditions and diseases associated with polycystin expression. Alt...
Invention Compounds for treatment of conditions and diseases. SCN1ASCN1ASCN1A gene and can modulate the exp...
2022 Invention Opa1 antisense oligomers for treatment of conditions and diseases. e.g.e.g.e.g., via modulation o...
Invention Compositions and methods for modulating splicing and protein expression. Alternative splicing ev...
Invention Compositions for treatment of conditions and diseases associated with polycystin expression. Alte...
2021 Invention Methods and compositions for modulating splicing of alternative introns. Provided herein are met...
Invention Methods and compositions for modulating splicing and translation. Alternative splicing events in...
Invention Antisense oligomers and uses thereof. Provided herein are methods and compositions for increasin...
Invention Antisense oligomers for treatment of autosomal dominant mental retardation-5 and dravet syndrome....
2020 Invention Antisense oligomers for treatment of conditions and diseases. Alternative splicing events in SCN1...
Invention Antisense oligomers for treatment of conditions and diseases. SCN1ASCN1ASCN1A gene can modulate t...
Invention Compositions and methods for modulating splicing and protein expression. Alternative splicing eve...
Invention Methods and compositions for modulating splicing of alternative introns. Provided herein are meth...
Invention Methods and compositions for modulating splicing and translation. Alternative splicing events in ...
2019 Invention Methods and compositions for treatment of cholesteryl ester storage disease. Provided herein are ...
2018 Invention Antisense oligomers and uses thereof. Provided herein are methods and compositions for increasing...
2016 Invention Compositions and methods for treatment of liver diseases. Provided herein are methods and composi...
Invention Compositions and methods for treatment of kidney diseases. Provided herein are methods and compos...
Invention Antisense oligomers for treatment of alagille syndrome. Provided herein are methods and compositi...
Invention Antisense oligomers for treatment of polycystic kidney disease. Provided herein are methods and c...
P/S Pharmaceuticals and medical preparations. Scientific research and development; Research and devel...
P/S Pharmaceutical preparations for the treatment of inherited diseases and genetic diseases, namely ...
P/S Research and development in the field of bioscience